ClinicalTrials.gg
Active, not recruitingNCT05552976SUCCESSOR-2Updated Sep 24, 2026

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

A Phase 3 interventional study of Mezigdomide and Carfilzomib in Relapsed or Refractory Multiple Myeloma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 204 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mezigdomide in Multiple Myeloma — 8 open to participants now, 11 under way, 2 of them phase 3. mezigdomide · Multiple Myeloma.

Enrollment
2nd of 13
606 · median 60
Started
2023
with 3 others
Phase 3
2 of 13
1 open now
Primary completion
2026-09
later than 0 of 10 live
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Bristol-Myers Squibb

Among the 13 studies testing mezigdomide in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 4 that started in 2023, is one of 2 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

8 of the 13 studies testing mezigdomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mezigdomide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mezigdomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • BMS-986348
  • CC-92480
  • Carfilzomib
  • Dexamethasone
  • Multiple Myeloma
  • Mezigdomide
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 606 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participant has documented diagnosis of multiple myeloma and , defined as any of the following:.

i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.

ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.

iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.

  • Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
  • Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \< 2 cycles are still eligible).
  • Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
  • Participant must have documented disease progression during or after their last antimyeloma regimen.

Exclusion criteria

Exclusion Criteria

  • Participant who has had prior treatment with mezigdomide or carfilzomib.
  • Participant has previously received stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
606 participants (actual)

Study arms

  • Experimental
    MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)

    Drug: Mezigdomide · Drug: Carfilzomib · Drug: Dexamethasone

  • Active comparator
    Kd (Carfilzomib + Dexamethasone)

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Specified dose on specified days

    Also known as: BMS-986348, CC-92480

  • Specified dose on specified days

    Also known as: Kyprolis

  • Specified dose on specified days

    Also known as: Decadron, Dex

07

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Recommended Mezigdomide Dose

    Stage 1 only

    Time frame: Up to 12 months

  2. Plasma concentrations of Mezigdomide in Combination with Carfilzomib and Dexamethasone

    Stage 1 only

    Time frame: Up to 176 days

  3. Overall Survival (OS)

    Time frame: Up to approximately 5 years

  4. Overall Response (OR)

    Time frame: Up to approximately 5 years

  5. Rate Of Very Good Partial Response (VGPR) Or Better (VGPRR)

    VGPRR will be calculated as the percentage of participants who achieve best response of VGPR or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.

    Time frame: Up to approximately 5 years

  6. Complete Response (CR) Or Better (CRR)

    CRR will be calculated as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma.

    Time frame: Up to approximately 5 years

  7. Time To Response (TTR)

    Time frame: Up to approximately 5 years

  8. Duration Of Response (DOR)

    Time frame: Up to approximately 5 years

  9. Time To Progression (TTP)

    Time frame: Up to approximately 5 years

  10. Time To Next Treatment (TTNT)

    Time frame: Up to approximately 5 years

  11. Progression-free Survival 2 (PFS-2)

    Time frame: Up to approximately 5 years

  12. Minimal Residual Disease (MRD) Negativity Rate

    Time frame: Up to approximately 5 years

  13. Number Of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 5 years

  14. Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

    Time frame: Up to approximately 5 years

  15. Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)

    The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

    Time frame: Up to approximately 5 years

08

Study locations

204 sites
  • Local Institution - 0046
    Mobile, Alabama 36604, United States
  • Local Institution - 0005
    Cerritos, California 90703, United States
  • Local Institution - 0190
    Irvine, California 92618, United States
  • Local Institution - 0187
    Los Angeles, California 90017, United States
  • Local Institution - 0344
    Santa Rosa, California 95403, United States
  • Local Institution - 0339
    Stockton, California 95204, United States
  • Local Institution - 0341
    Fort Myers, Florida 33901, United States
  • Local Institution - 0342
    St. Petersburg, Florida 33705, United States
  • Local Institution - 0340
    West Palm Beach, Florida 33401, United States
  • Local Institution - 0348
    Atlanta, Georgia 30303, United States
  • Local Institution - 0291
    Atlanta, Georgia 30322, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Local Institution - 0289
    Annapolis, Maryland 21401, United States
  • Local Institution - 0204
    Boston, Massachusetts 02215, United States
  • Local Institution - 0346
    Minneapolis, Minnesota 55404, United States
  • Local Institution - 0222
    Little Silver, New Jersey 07739, United States
  • Local Institution - 0199
    The Bronx, New York 10467, United States
  • Local Institution - 0322
    Cleveland, Ohio 44106, United States
  • Local Institution - 0172
    Columbus, Ohio 43214, United States
  • Local Institution - 0321
    Providence, Rhode Island 02903, United States
  • Local Institution - 0338
    Greer, South Carolina 29650, United States
  • Local Institution - 0349
    Chattanooga, Tennessee 37404, United States
  • Local Institution - 0323
    Nashville, Tennessee 37203, United States
  • Local Institution - 0337
    Fort Worth, Texas 76104, United States
  • Local Institution - 0328
    Houston, Texas 77025, United States
  • Local Institution - 0044
    Houston, Texas 77030, United States
  • Local Institution - 0195
    Temple, Texas 76508, United States
  • Local Institution - 0345
    Norfolk, Virginia 23502, United States
  • Local Institution - 0343
    Roanoke, Virginia 24014, United States
  • Local Institution - 0006
    Tacoma, Washington 98405, United States
  • Local Institution - 0347
    Vancouver, Washington 98684, United States
  • Local Institution - 0243
    Morgantown, West Virginia 26506, United States
  • Local Institution - 0336
    Marshfield, Wisconsin 54449, United States
  • Local Institution - 0008
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0079
    ABB, Buenos Aires F.D. C1199ABB, Argentina
  • Local Institution - 0182
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0319
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0150
    Buenos Aires, 1431, Argentina
  • Local Institution - 0151
    Córdoba, 5000, Argentina
  • Local Institution - 0077
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0160
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0263
    Port Macquarie, New South Wales 2444, Australia
  • Local Institution - 0078
    St Leonards, New South Wales 2065, Australia
  • Local Institution - 0026
    Sydney, New South Wales 2010, Australia
  • Local Institution - 0024
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0131
    Bendigo, Victoria 3550, Australia
  • Local Institution - 0224
    East Melbourne, Victoria 3002, Australia
  • Local Institution - 0127
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0025
    Melbourne, Victoria 3065, Australia
  • Local Institution - 0266
    Vienna, State of Vienna 1060, Austria
  • Local Institution - 0020
    Linz, 4020, Austria
  • Local Institution - 0017
    Vienna, 1090, Austria
  • Local Institution - 0121
    Salvador, Estado de Bahia 41253-190, Brazil
  • Local Institution - 0076
    Porto Alegre, Rio Grande do Sul 90470-340, Brazil
  • Local Institution - 0085
    São Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0075
    Rio de Janeiro, 20775-001, Brazil
  • Local Institution - 0073
    São Paulo, 04537-080, Brazil
  • Local Institution - 0305
    Plovdiv, 4002, Bulgaria
  • Local Institution - 0309
    Sofia, 1407, Bulgaria
  • Local Institution - 0304
    Sofia, 1431, Bulgaria
  • Local Institution - 0183
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0275
    London, Ontario N6A 5W9, Canada
  • Local Institution - 0184
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0061
    Beijing, Beijing Municipality 100020, China
  • Local Institution - 0057
    Beijing, Beijing Municipality 100043, China
  • Local Institution - 0056
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0123
    Fuzhou, Fujian 350000, China
  • Local Institution - 0138
    Guangzhou, Guangdong 510000, China
  • Local Institution - 0051
    Zhengzhou, Henan 450008, China
  • Local Institution - 0066
    Wuhan, Hubei 430002, China
  • Local Institution - 0054
    Wuhan, Hubei 430030, China
  • Local Institution - 0071
    Changsha, Hunan 410013, China
  • Local Institution - 0103
    Changsha, Hunan 410013, China
  • Local Institution - 0180
    Nanjing, Jiangsu 210009, China
  • Local Institution - 0111
    Nantong, Jiangsu 226001, China
  • Local Institution - 0104
    Suzhou, Jiangsu 215006, China
  • Local Institution - 0069
    Wuxi, Jiangsu 214023, China
  • Local Institution - 0095
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0052
    Changchun, Jilin 130021, China
  • Local Institution - 0096
    Shenyang, Liaoning 110001, China
  • Local Institution - 0176
    Shenyang, Liaoning 110004, China
  • Local Institution - 0060
    Xi'an, Shaanxi 710126, China
  • Local Institution - 0072
    Jinan, Shandong 250012, China
  • Local Institution - 0118
    Shanghai, Shanghai Municipality 200025, China
  • Local Institution - 0317
    Shanghai, Shanghai Municipality 200080, China
  • Local Institution - 0091
    Tianjin, Tianjin Municipality 300060, China
  • Local Institution - 0058
    Kunming, Yunnan 650101, China
  • Local Institution - 0050
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0115
    Wenzhou, Zhejiang 32500, China
  • Local Institution - 0059
    Taiyuan, 030032, China
  • Local Institution - 0153
    Medellín, Antioquia 05034, Colombia
  • Local Institution - 0156
    Valledupar, Cesar Department 200001, Colombia
  • Local Institution - 0154
    Bogota, Cundinamarca 111151, Colombia
  • Local Institution - 0324
    Piedecuesta, Santander Department 681017, Colombia
  • Local Institution - 0155
    Cali, 760035, Colombia
  • Local Institution - 0032
    Aarhus, Central Jutland 8200, Denmark
  • Local Institution - 0065
    Roskilde, Region Sjælland 4000, Denmark
  • Local Institution - 0129
    Odense, Region Syddanmark 5000, Denmark
  • Local Institution - 0125
    Vejle, 7100, Denmark
  • Local Institution - 0124
    Ulm, Baden-Wurttemberg 89081, Germany

Showing the first 100 of 204 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoe E, Galvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet. 2026 Jul 18;408(10551):219-233. doi: 10.1016/S0140-6736(26)01088-3. Epub 2026 Jun 14. PubMed 42289183 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2026, 44 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 44 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Jan 10, 2023
Primary completionEst.
Sep 28, 2026
CompletionEst.
Jul 25, 2029
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05552976
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Jan 10, 2023
Primary completion
Sep 28, 2026 (estimated)
Completion
Jul 25, 2029 (estimated)
Last update
Sep 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion